

Steven E Schild

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3760281/publications.pdf>

Version: 2024-02-01

504
papers

25,977
citations

9756

73
h-index

8599

146
g-index

507
all docs

507
docs citations

507
times ranked

20647
citing authors

#	ARTICLE	IF	CITATIONS
1	Biologically Effective Dose and Rectal Bleeding in Definitive Proton Therapy for Prostate Cancer. <i>International Journal of Particle Therapy</i> , 2022, 8, 37-46.	0.9	0
2	Perâ€voxel constraints to minimize hot spots in linear energy transferâ€guided robust optimization for base of skull head and neck cancer patients in IMPT. <i>Medical Physics</i> , 2022, 49, 632-647.	1.6	12
3	Gastroesophageal reflux disease and paraneoplastic neurological syndrome associated with <sc>longâ€term</sc> survival in limited stage <sc>smallâ€cell</sc> lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 925-933.	0.8	2
4	Radiotherapy with or without Decompressive Surgery for Metastatic Spinal Cord Compression: A Retrospective Matched-Pair Study Including Data from Prospectively Evaluated Patients. <i>Cancers</i> , 2022, 14, 1260.	1.7	7
5	Estimating the Probability of Not Completing the Intended Course of Thoracic Radiotherapy for Lung Cancer. <i>Anticancer Research</i> , 2022, 42, 1973-1977.	0.5	1
6	Empirical Relative Biological Effectiveness (RBE) for Mandible Osteoradionecrosis (ORN) in Head and Neck Cancer Patients Treated With Pencil-Beam-Scanning Proton Therapy (PBSPT): A Retrospective, Case-Matched Cohort Study. <i>Frontiers in Oncology</i> , 2022, 12, 843175.	1.3	13
7	Clinical necessity of multi-image based (4DMIB) optimization for targets affected by respiratory motion and treated with scanned particle therapy â€ A comprehensive review. <i>Radiotherapy and Oncology</i> , 2022, 169, 77-85.	0.3	12
8	A New and Easy-to-Use Survival Score for Patients Irradiated for Metastatic Epidural Spinal Cord Compression. <i>Practical Radiation Oncology</i> , 2022, 12, 354-362.	1.1	5
9	Risk Factors for Sleep Problems Prior to Radiochemotherapy for Malignant Gliomas. <i>In Vivo</i> , 2022, 36, 325-329.	0.6	4
10	GPUâ€accelerated Monte Carloâ€based online adaptive proton therapy: A feasibility study. <i>Medical Physics</i> , 2022, 49, 3550-3563.	1.6	10
11	Prognostic Factors of Survival After Radiotherapy for Lung Cancerâ€The Impact of Smoking Pack Years. <i>In Vivo</i> , 2022, 36, 1297-1301.	0.6	1
12	Radiation recall dermatitis: A review of the literature. <i>Seminars in Oncology</i> , 2022, 49, 152-159.	0.8	11
13	Risk Factors for Xerostomia Following Radiotherapy of Head-and-Neck Cancers. <i>Anticancer Research</i> , 2022, 42, 2657-2663.	0.5	6
14	Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e317-e320.	1.1	10
15	Prognostic Value of Preclinical Markers after Radiotherapy of Metastatic Spinal Cord Compressionâ€An Additional Analysis of Patients from Two Prospective Trials. <i>Cancers</i> , 2022, 14, 2547.	1.7	1
16	Impact of Cardiac Dose on Overall Survival in Lung Stereotactic Body Radiotherapy (SBRT) Compared to Conventionally Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC). <i>Journal of Cancer Therapy</i> , 2021, 12, 409-423.	0.1	3
17	Palliative Radiotherapy of Primary Glioblastoma. <i>In Vivo</i> , 2021, 35, 483-487.	0.6	4
18	Comparison of Conventional Fractionation and Accelerated Fractionation With Concomitant Boost for Radiotherapy of Non-metastatic Stage IV Head-and-Neck Cancer. <i>In Vivo</i> , 2021, 35, 411-415.	0.6	10

#	ARTICLE	IF	CITATIONS
19	A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. <i>Anticancer Research</i> , 2021, 41, 379-384.	0.5	2
20	Using Novel Statistical Techniques to Accurately Determine the Predictive Dose Range in a Study of Overall Survival after Definitive Radiotherapy for Stage III Non-Small Cell Lung Cancer in Association with Heart Dose. <i>Journal of Cancer Therapy</i> , 2021, 12, 505-529.	0.1	2
21	Comparison of 5 Gy and 10 Gy for metastatic spinal cord compression using data from three prospective trials. <i>Radiation Oncology</i> , 2021, 16, 7.	1.2	10
22	Proton beam radiotherapy for patients with early-stage and advanced lung cancer: a narrative review with contemporary clinical recommendations. <i>Journal of Thoracic Disease</i> , 2021, 13, 1270-1285.	0.6	6
23	Consensus Statement on Proton Therapy in Mesothelioma. <i>Practical Radiation Oncology</i> , 2021, 11, 119-133.	1.1	11
24	Karnofsky Performance Score – An Independent Prognostic Factor of Survival After Palliative Irradiation for Sino-nasal Cancer. <i>Anticancer Research</i> , 2021, 41, 2495-2499.	0.5	3
25	Palliative Local Radiotherapy for Advanced Squamous Cell Carcinoma of the Head-and-Neck: Prognostic Factors of Survival. <i>Anticancer Research</i> , 2021, 41, 3205-3210.	0.5	0
26	Dose-volume histogram parameters and patient-reported EPIC-Bowel domain in prostate cancer proton therapy. <i>Radiation Oncology Journal</i> , 2021, 39, 122-128.	0.7	0
27	Technical Note: 4D robust optimization in small spot intensity-modulated proton therapy (IMPT) for distal esophageal carcinoma. <i>Medical Physics</i> , 2021, 48, 4636-4647.	1.6	14
28	EMBR-03. PINEOBLASTOMA: A POOLED OUTCOME STUDY OF NORTH AMERICAN AND AUSTRALIAN THERAPEUTIC DATA. <i>Neuro-Oncology</i> , 2021, 23, i6-i6.	0.6	0
29	A New Survival Score for Patients Scheduled for Palliative Irradiation of Locally Advanced Carcinoma of the Head-and-Neck. <i>Anticancer Research</i> , 2021, 41, 3055-3058.	0.5	2
30	Exploratory Investigation of Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity Modulated Proton Therapy (IMPT). <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1189-1199.	0.4	15
31	Technical Note: Multiple energy extraction techniques for synchrotron-based proton delivery systems may exacerbate motion interplay effects in lung cancer treatments. <i>Medical Physics</i> , 2021, 48, 4812-4823.	1.6	1
32	Frequency and Risk Factors of Sleep Disturbances in Patients With Prostate Cancer Assigned to Local or Loco-regional Radiotherapy. <i>Anticancer Research</i> , 2021, 41, 5165-5169.	0.5	4
33	Sleep Disorders Prior to Adjuvant Radiation Therapy for Gynecological Malignancies. <i>Anticancer Research</i> , 2021, 41, 4407-4410.	0.5	4
34	Evaluation of Pre-radiotherapy Sleep Disorders in Patients With Rectal or Anal Cancer. <i>Anticancer Research</i> , 2021, 41, 4439-4442.	0.5	8
35	Risk Factors for Sleep Disturbances in Patients Scheduled for Radiotherapy of Head-and-Neck Cancer. <i>Anticancer Research</i> , 2021, 41, 5065-5069.	0.5	5
36	Sleep Disorders Before and During the COVID-19 Pandemic in Patients Assigned to Adjuvant Radiotherapy for Breast Cancer. <i>In Vivo</i> , 2021, 35, 2253-2260.	0.6	14

#	ARTICLE	IF	CITATIONS
37	Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN). <i>Anticancer Research</i> , 2021, 41, 477-484.	0.5	6
38	Accelerated Fractionation Plus Chemotherapy <i>versus</i> Conventionally Fractionated Radiochemotherapy for Unresectable Head-and-Neck Cancer. <i>Anticancer Research</i> , 2021, 41, 877-884.	0.5	7
39	Palliative Radiotherapy for Cutaneous Squamous Cell Carcinoma of the Head-and-Neck Region. <i>In Vivo</i> , 2021, 35, 2283-2288.	0.6	4
40	Emotional Problems Prior to Adjuvant Radiation Therapy for Breast Cancer. <i>In Vivo</i> , 2021, 35, 2763-2770.	0.6	5
41	Sleep Disturbances in Lung Cancer Patients Assigned to Definitive or Adjuvant Irradiation. <i>In Vivo</i> , 2021, 35, 3333-3337.	0.6	5
42	Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617. <i>Cancers</i> , 2021, 13, 6193.	1.7	39
43	Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience. <i>Advances in Radiation Oncology</i> , 2020, 5, 450-458.	0.6	18
44	A Simple Clinical Instrument to Predict the Survival Probability of Breast Cancer Patients Receiving Radiotherapy for Bone Metastases. <i>Anticancer Research</i> , 2020, 40, 367-371.	0.5	3
45	Precision Radiation Therapy for Metastatic Spinal Cord Compression: Final Results of the PRE-MODE Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 780-789.	0.4	18
46	Hybrid 3D analytical linear energy transfer calculation algorithm based on precalculated data from Monte Carlo simulations. <i>Medical Physics</i> , 2020, 47, 745-752.	1.6	20
47	An easy-to-use scoring system to estimate the survival of patients irradiated for bone metastases from lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1067-1073.	1.3	5
48	Beam angle comparison for distal esophageal carcinoma patients treated with intensity-modulated proton therapy. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 141-152.	0.8	15
49	Intensity-modulated proton therapy (IMPT) interplay effect evaluation of asymmetric breathing with simultaneous uncertainty considerations in patients with non-small cell lung cancer. <i>Medical Physics</i> , 2020, 47, 5428-5440.	1.6	20
50	Performance Status Is Associated With Survival in Elderly Patients Irradiated for Cerebral Metastases from Prostate Cancer. <i>Anticancer Research</i> , 2020, 40, 1665-1668.	0.5	5
51	Estimating the Lifespan of Elderly Patients With Cerebral Metastases from Kidney Cancer. <i>In Vivo</i> , 2020, 34, 1321-1324.	0.6	2
52	The Results of Whole-brain Radiotherapy for Elderly Patients With Brain Metastases from Urinary Bladder Cancer. <i>In Vivo</i> , 2020, 34, 1317-1320.	0.6	1
53	Radiotherapy of Grade III Gliomas: Identification of Clinical Prognostic Factors for Local Tumor Control and Survival. <i>In Vivo</i> , 2020, 34, 3627-3630.	0.6	1
54	Three-Dimensionally Printed On-Skin Radiation Shields Using High-Density Filament. <i>Practical Radiation Oncology</i> , 2020, 10, e543-e550.	1.1	4

#	ARTICLE	IF	CITATIONS
55	Pre-operative Seizures in Patients With Single Brain Metastasis Treated With Resection Plus Whole-Brain Irradiation and a Boost. <i>In Vivo</i> , 2020, 34, 2705-2709.	0.6	2
56	Linear accelerator-based single-fraction stereotactic body radiotherapy for symptomatic vertebral body hemangiomas: The Mayo Clinic experience. <i>Journal of Clinical Neuroscience</i> , 2020, 80, 74-78.	0.8	7
57	Development of a multivariable prediction model to estimate the remaining lifespan of elderly patients with cerebral metastases from small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1433-1440.	1.3	2
58	Optimizing the Radiotherapy of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1559-1560.	0.5	4
59	A Pragmatic Approach to Cancer Staging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 830.	0.4	0
60	A Simple Implement for Assessing the Survival of Elderly Patients With Melanoma Irradiated for Cerebral Metastases. <i>In Vivo</i> , 2020, 34, 1361-1364.	0.6	2
61	Detecting spatial susceptibility to cardiac toxicity of radiation therapy for lung cancer. <i>IIEE Transactions on Healthcare Systems Engineering</i> , 2020, 10, 243-250.	1.2	6
62	Predicting the Risk of Subsequent Distant Brain Metastases After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy in Elderly Patients. <i>Anticancer Research</i> , 2020, 40, 4081-4086.	0.5	0
63	Prognostic Factors of Local Control and Survival in Patients Irradiated for Glioblastoma Multiforme (GBM). <i>Anticancer Research</i> , 2020, 40, 7025-7030.	0.5	3
64	Re-Irradiation for Recurrent Glioblastoma Multiforme. <i>Anticancer Research</i> , 2020, 40, 7077-7081.	0.5	9
65	Regarding Small Cell, Big Dilemma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 865.	0.4	0
66	Clinical Prognostic Factors for Local Control and Survival After Irradiation of Grade II Gliomas. <i>In Vivo</i> , 2020, 34, 3719-3722.	0.6	2
67	Remaining Lifespan of Patients Aged ≥65 Years Receiving Whole-brain Irradiation for Metastases from Cancer of Unknown Primary. <i>Anticancer Research</i> , 2020, 40, 2261-2264.	0.5	3
68	Elderly Patients With Single Brain Metastasis – Overall Survival After Surgery Plus Whole-Brain Irradiation and a Radiation Boost. <i>In Vivo</i> , 2020, 34, 1421-1425.	0.6	1
69	Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase II trial (LEOPARD-2). <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 795-804.	1.0	9
70	A Scoring Tool to Estimate the Survival of Elderly Patients With Brain Metastases from Esophageal Cancer Receiving Whole-brain Irradiation. <i>Anticancer Research</i> , 2020, 40, 1661-1664.	0.5	1
71	Seizures Prior to Whole-brain Irradiation for Metastatic Disease: Prevalence, Risk Factors and Association With Survival. <i>Anticancer Research</i> , 2020, 40, 3429-3434.	0.5	1
72	Extra-cerebral Metastasis – An Independent Predictor of Survival in Older Patients With Brain Metastases Receiving a Local Therapy Plus Whole-Brain Radiotherapy (WBRT). <i>Anticancer Research</i> , 2020, 40, 2841-2845.	0.5	4

#	ARTICLE	IF	CITATIONS
73	Interval Between Cancer Diagnosis and Radiotherapy – An Independent Prognostic Factor of Survival in Patients Irradiated for Bone Metastases from Kidney Cancer. <i>In Vivo</i> , 2020, 34, 767-770.	0.6	1
74	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 631-640.	0.4	40
75	Survival After Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiotherapy (FSRT) for Cerebral Metastases in the Elderly. <i>In Vivo</i> , 2020, 34, 1909-1913.	0.6	3
76	Seizures Prior to Radiotherapy of Gliomas: Prevalence, Risk Factors and Survival Prognosis. <i>Anticancer Research</i> , 2020, 40, 3961-3965.	0.5	5
77	Robust Optimization for Intensity Modulated Proton Therapy to Redistribute High Linear Energy Transfer from Nearby Critical Organs to Tumors in Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 181-193.	0.4	43
78	Eastern Cooperative Oncology Group Performance Score Is Associated With Survival After Radiotherapy of Bone Metastases from Prostate Cancer. <i>In Vivo</i> , 2020, 34, 679-682.	0.6	3
79	A Disease-specific Score for Estimating Survival After Irradiation of Bone Metastases from Colorectal Cancer. <i>Anticancer Research</i> , 2020, 40, 287-291.	0.5	1
80	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 146, 223-229.	0.3	168
81	Individualisation of Radiation Therapy for Older Persons With Secondary Brain Lesions from Carcinoma of the Breast. <i>Anticancer Research</i> , 2020, 40, 2271-2274.	0.5	3
82	An Easy-To-Use Survival Score Compared to Existing Tools for Older Patients with Cerebral Metastases from Colorectal Cancer. <i>Cancers</i> , 2020, 12, 833.	1.7	5
83	An Instrument to Guide Physicians when Estimating the Survival of Elderly Patients With Brain Metastasis from Gynecological Cancer. <i>Anticancer Research</i> , 2020, 40, 2257-2260.	0.5	3
84	Evaluation of Five Survival Scores in a Cohort of Elderly Patients With Cerebral Metastasis from Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 2847-2851.	0.5	2
85	Occurrence of Seizures Prior to Single-fraction Radiosurgery or Multi-fraction Stereotactic Radiotherapy in Patients With Very Few Brain Metastases. <i>Anticancer Research</i> , 2020, 40, 3499-3504.	0.5	1
86	Pre-Treatment Seizures in Patients With 1-3 Cerebral Metastases Receiving Local Therapies Plus Whole-brain Radiotherapy. <i>In Vivo</i> , 2020, 34, 2727-2731.	0.6	2
87	Re-Evaluation of Prognostic Factors for Survival After Radiotherapy of Cerebral Gliomas: A Supplementary Analysis to a Previous Study. <i>Anticancer Research</i> , 2020, 40, 6513-6515.	0.5	2
88	Prognostic Role of Pre-Treatment Symptoms for Survival of Patients Irradiated for Brain Metastases. <i>Anticancer Research</i> , 2019, 39, 4273-4277.	0.5	4
89	Clinical evaluation of fitness to drive in patients with brain metastases. <i>Neuro-Oncology Practice</i> , 2019, 6, 484-489.	1.0	2
90	Technical Note: Treatment planning system (TPS) approximations matter – comparing intensity-modulated proton therapy (IMPT) plan quality and robustness between a commercial and an in-house developed TPS for nonsmall cell lung cancer (NSCLC). <i>Medical Physics</i> , 2019, 46, 4755-4762.	1.6	19

#	ARTICLE	IF	CITATIONS
91	Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis. <i>Radiotherapy and Oncology</i> , 2019, 141, 56-61.	0.3	71
92	The Search for Optimal Stereotactic Body Radiotherapy Dose in Inoperable, Centrally Located Non-Small-Cell Lung Cancer Continues. <i>Journal of Clinical Oncology</i> , 2019, 37, 2697-2699.	0.8	8
93	Patient-Reported Outcomes—Secondary Analysis of the SCORE-2 Trial Comparing 4 Gy × 5 to 3 Gy × 10 for Metastatic Epidural Spinal Cord Compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 760-764.	0.4	9
94	A randomized trial (RAREST-01) comparing Mepitel® Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN). <i>Radiotherapy and Oncology</i> , 2019, 139, 79-82.	0.3	25
95	Rational radiotherapy: The role in node-negative squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2019, , .	0.6	0
96	Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 686-696.	0.4	15
97	Impact of planned dose reporting methods on Gamma pass rates for IROC lung and liver motion phantoms treated with pencil beam scanning protons. <i>Radiation Oncology</i> , 2019, 14, 108.	1.2	4
98	Diagnosis-specific WBRT-30-CRC Score for Estimating Survival of Patients Irradiated for Brain Metastases from Colorectal Cancer. <i>Anticancer Research</i> , 2019, 39, 2569-2574.	0.5	4
99	Small-cell Lung Cancer in Very Elderly (≥ 80 Years) Patients. <i>Clinical Lung Cancer</i> , 2019, 20, 313-321.	1.1	15
100	Estimating Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Whole-brain Radiotherapy With a New Tool. <i>Anticancer Research</i> , 2019, 39, 2091-2095.	0.5	5
101	Predictors of Outcomes and a Scoring System for Estimating Survival in Patients Treated With Radiotherapy for Metastatic Spinal Cord Compression From Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 322-329.	1.1	10
102	Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses. <i>Anticancer Research</i> , 2019, 39, 1343-1346.	0.5	4
103	Comparison of Diagnosis-specific Survival Scores for Patients With Cerebral Metastases from Malignant Melanoma Including the New WBRT-30-MM. <i>Anticancer Research</i> , 2019, 39, 1501-1505.	0.5	3
104	A New Diagnosis-Specific Survival Score for Patients to be Irradiated for Brain Metastases from Non-small Cell Lung Cancer. <i>Lung</i> , 2019, 197, 321-326.	1.4	9
105	Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases. <i>Cancers</i> , 2019, 11, 233.	1.7	7
106	The PEMBRO-RT phase II randomized trial and the evolution of therapy for metastatic non-small cell lung cancer: a historical perspective. <i>Annals of Translational Medicine</i> , 2019, 7, S294-S294.	0.7	0
107	Results of Tri-Modality Therapy for Rectal Cancer in Elderly Patients. <i>Anticancer Research</i> , 2019, 39, 6217-6222.	0.5	3
108	Prognostic factors and a new scoring system for survival of patients irradiated for bone metastases. <i>BMC Cancer</i> , 2019, 19, 1156.	1.1	10

#	ARTICLE	IF	CITATIONS
109	Clinical Validation of a Ray-Casting Analytical Dose Engine for Spot Scanning Proton Delivery Systems. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381988718.	0.8	15
110	A novel and individualized robust optimization method using normalized dose interval volume constraints (<sc>NDIVC</sc>) for intensityâ€modulated proton radiotherapy. <i>Medical Physics</i> , 2019, 46, 382-393.	1.6	16
111	Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Nonâ€Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 298-303.	0.5	13
112	A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limitedâ€stage small cell lung cancer in elderly patients versus younger patients. <i>Cancer</i> , 2019, 125, 382-390.	2.0	14
113	A new instrument for predicting survival of patients with cerebral metastases from breast cancer developed in a homogeneously treated cohort. <i>Radiology and Oncology</i> , 2019, 53, 219-224.	0.6	3
114	NCCN Guidelines Insights: Nonâ€Small Cell Lung Cancer, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1464-1472.	2.3	556
115	Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Nonâ€Small Cell Lung Cancer: The Mayo Clinic Experience. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018, 2, 40-48.	1.2	19
116	Data collection of patient outcomes: one institutionâ€™s experience. <i>Journal of Radiation Research</i> , 2018, 59, i19-i24.	0.8	5
117	Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stageâ€SCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1171-1182.	0.5	17
118	Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 479-489.	0.4	44
119	Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 177-185.	0.4	35
120	Fatal Radiation Pneumonitis in Patients With Subclinical Interstitial Lung Disease. <i>Clinical Lung Cancer</i> , 2018, 19, e417-e420.	1.1	13
121	Robust optimization in <sc>IMPT</sc> using quadratic objective functions to account for the minimum <sc>MU</sc> constraint. <i>Medical Physics</i> , 2018, 45, 460-469.	1.6	34
122	Stereotactic body radiotherapy for early-stage non-small cell lung cancer has low post-treatment mortality. <i>Journal of Thoracic Disease</i> , 2018, 10, S2004-S2006.	0.6	0
123	A scoring system to predict local progression-free survival in patients irradiated with 20â€™Gy in 5 fractions for malignant spinal cord compression. <i>Radiation Oncology</i> , 2018, 13, 257.	1.2	3
124	Potential Prognostic Factors of Downstaging Following Preoperative Chemoradiation for High Rectal Cancer. <i>In Vivo</i> , 2018, 32, 1481-1484.	0.6	4
125	Prognostic Factors and a Survival Score in Patients Irradiated for Metastatic Epidural Spinal Cord Compression from Urothelial Carcinoma Cancer of the Bladder. <i>Anticancer Research</i> , 2018, 38, 6841-6846.	0.5	3
126	A Matched-Pair Study Comparing Surgery Plus Neoadjuvant Radio-Chemotherapy and Surgery Alone for High Rectal Cancers. <i>Anticancer Research</i> , 2018, 38, 6877-6880.	0.5	6

#	ARTICLE	IF	CITATIONS
127	Whole-Brain Radiotherapy (WBRT) for Brain Metastases: Does the Interval Between Imaging and Treatment Matter?. <i>Anticancer Research</i> , 2018, 38, 6835-6840.	0.5	6
128	Outcomes After Radiotherapy Alone for Metastatic Spinal Cord Compression in Patients with Oligo-metastatic Breast Cancer. <i>Anticancer Research</i> , 2018, 38, 6897-6903.	0.5	4
129	Smallâ€spot intensityâ€modulated proton therapy and volumetricâ€modulated arc therapies for patients with locally advanced nonâ€smallâ€cell lung cancer: A dosimetric comparative study. <i>Journal of Applied Clinical Medical Physics</i> , 2018, 19, 140-148.	0.8	32
130	Role of Neoadjuvant Radio-chemotherapy for the Treatment of High Rectal Cancer. <i>Anticancer Research</i> , 2018, 38, 5371-5377.	0.5	6
131	A Specific Survival Score for Patients Receiving Local Therapy for Single Brain Metastasis from a Gynecological Malignancy. <i>In Vivo</i> , 2018, 32, 825-828.	0.6	16
132	NCCN Guidelines Insights: Nonâ€Small Cell Lung Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 807-821.	2.3	394
133	A Tool to Predict the Probability of Intracerebral Recurrence or New Cerebral Metastases After Whole-brain Irradiation in Patients with Head-and-Neck Cancer. <i>Anticancer Research</i> , 2018, 38, 4199-4202.	0.5	11
134	1x8 Gy versus 5x4 Gy for metastatic epidural spinal cord compression: a matched-pair study of three prognostic patient subgroups. <i>Radiation Oncology</i> , 2018, 13, 21.	1.2	10
135	An Instrument for Estimating the 6-Month Survival Probability After Whole-brain Irradiation Alone for Cerebral Metastases from Gynecological Cancer. <i>Anticancer Research</i> , 2018, 38, 3753-3756.	0.5	13
136	Hyperfractionated or Accelerated Hyperfractionated Re-irradiation with 42 Gy in Combination with Paclitaxel for Secondary/Recurrent Head-and-Neck Cancer. <i>Anticancer Research</i> , 2018, 38, 3653-3656.	0.5	4
137	Stereotactic Radiosurgery Alone for One to Two Brain Metastases from Cancer of Unknown Primary. <i>Anticancer Research</i> , 2018, 38, 565-567.	0.5	6
138	Predictive Factors for Local Control and Survival in Patients with Cancer of Unknown Primary (CUP) Irradiated for Cerebral Metastases. <i>Anticancer Research</i> , 2018, 38, 2415-2418.	0.5	6
139	Comparison of Two Radiotherapy Regimens for Metastatic Spinal Cord Compression: Subgroup Analyses from a Randomized Trial. <i>Anticancer Research</i> , 2018, 38, 1009-1015.	0.5	3
140	Metastatic Epidural Spinal Cord Compression: Conventional Radiotherapy. , 2018, , 159-176.		0
141	Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain Metastases. <i>In Vivo</i> , 2018, 32, 381-384.	0.6	9
142	A New Scoring-system for Estimating Overall Survival After Radiotherapy of Recurrent Head and Neck Cancers. <i>Anticancer Research</i> , 2018, 38, 1611-1613.	0.5	0
143	Performance Status and Number of Metastatic Extra-cerebral Sites Predict Survival After Radiotherapy of Brain Metastases from Thyroid Cancer. <i>Anticancer Research</i> , 2018, 38, 2391-2394.	0.5	3
144	Predicting Survival After Whole-brain Irradiation for Cerebral Metastases in Patients with Cancer of the Bladder. <i>In Vivo</i> , 2018, 32, 633-636.	0.6	5

#	ARTICLE	IF	CITATIONS
145	Predicting the Risk of Developing New Cerebral Lesions After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Brain Metastases from Renal Cell Carcinoma. <i>Anticancer Research</i> , 2018, 38, 2973-2976.	0.5	4
146	A Score to Identify Patients with Brain Metastases from Colorectal Cancer Who May Benefit from Whole-brain Radiotherapy in Addition to Stereotactic Radiosurgery/Radiotherapy. <i>Anticancer Research</i> , 2018, 38, 3111-3114.	0.5	5
147	A matched-pair study comparing whole-brain irradiation alone to radiosurgery or fractionated stereotactic radiotherapy alone in patients irradiated for up to three brain metastases. <i>BMC Cancer</i> , 2017, 17, 30.	1.1	9
148	Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). <i>Journal of Thoracic Oncology</i> , 2017, 12, 697-703.	0.5	16
149	Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer. <i>Lung</i> , 2017, 195, 217-224.	1.4	35
150	GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer. <i>British Journal of Radiology</i> , 2017, 90, 20170174.	1.0	8
151	Exploratory study of the association of volumetric modulated arc therapy (VMAT) plan robustness with local failure in head and neck cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2017, 18, 76-83.	0.8	39
152	Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 504-535.	2.3	994
153	Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e969-e975.	0.9	41
154	A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 1021-1025.	0.4	11
155	Robust treatment planning with conditional value at risk chance constraints in intensity-modulated proton therapy. <i>Medical Physics</i> , 2017, 44, 28-36.	1.6	29
156	Robust intensity-modulated proton therapy to reduce high linear energy transfer in organs at risk. <i>Medical Physics</i> , 2017, 44, 6138-6147.	1.6	58
157	Mixed integer programming with dose-volume constraints in intensity-modulated proton therapy. <i>Journal of Applied Clinical Medical Physics</i> , 2017, 18, 29-35.	0.8	7
158	A New Scoring Tool to Assess Overall Survival in Patients With Intracerebral Metastases From Gynecological Cancers. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 597-602.	1.2	8
159	Photon and Proton Radiation Therapy Utilization in a Population of More Than 100 Million Commercially Insured Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1078-1082.	0.4	21
160	A matched-pair analysis comparing whole-brain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases. <i>Radiation Oncology</i> , 2017, 12, 69.	1.2	14
161	Role of the overall treatment time of radiotherapy with 10-13 Gy for outcomes in patients with metastatic spinal cord compression. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 388-393.	0.9	1
162	Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 1021-1027.	0.8	13

#	ARTICLE	IF	CITATIONS
163	Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 56-62.	0.8	557
164	Results of a multicenter study investigating the potential impact of the overall treatment time on outcomes of radiation therapy alone with 5A–4 Gy for metastatic epidural spinal cord compression. <i>Practical Radiation Oncology</i> , 2017, 7, 137-144.	1.1	3
165	Prophylactic Cranial Irradiation Following Surgical Resection of Early-Stage Small-Cell Lung Cancer: A Review of the Literature. <i>Frontiers in Oncology</i> , 2017, 7, 228.	1.3	9
166	Prophylactic Cranial Irradiation for Extensive Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, 732-738.	2.5	22
167	Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. <i>Journal of Clinical Oncology</i> , 2017, 35, 2885-2892.	0.8	68
168	Survival Following Palliative External-beam Radiotherapy of Locally Advanced and Metastatic Liver Cancer. <i>Anticancer Research</i> , 2017, 37, 203-206.	0.5	2
169	Development of a Survival Score for Patients with Cerebral Metastases from Melanoma. <i>Anticancer Research</i> , 2017, 37, 249-252.	0.5	6
170	Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer. <i>Anticancer Research</i> , 2017, 37, 1485-1488.	0.5	6
171	Simplified Comorbidity Score and Eastern Cooperative Oncology Group Performance Score Predicts Survival in Patients Receiving Organ-preserving Treatment for Bladder Cancer. <i>Anticancer Research</i> , 2017, 37, 2693-2696.	0.5	14
172	Factors Impacting the Overall Survival of Patients Irradiated for Invasive Carcinoma of the Urinary Bladder. <i>In Vivo</i> , 2017, 31, 741-744.	0.6	4
173	Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. <i>Journal of Cancer Therapy</i> , 2017, 08, 73-85.	0.1	18
174	Clinical Factors Associated with Treatment Outcomes following Whole-brain Irradiation in Patients with Prostate Cancer. <i>In Vivo</i> , 2017, 31, 35-38.	0.6	4
175	Outcomes After Radio(chemo)therapy for Non-Metastatic Bile Duct Cancer. <i>In Vivo</i> , 2017, 31, 117-120.	0.6	1
176	A Survival Score for Patients Assigned to Palliative Radiotherapy for Metastatic Bladder Cancer. <i>Anticancer Research</i> , 2017, 37, 1481-1484.	0.5	5
177	A New Prognostic Instrument Specifically Designed for Patients Irradiated for Recurrent Carcinoma of the Bladder. <i>In Vivo</i> , 2017, 31, 435-438.	0.6	3
178	Radiotherapy of Primary or Recurrent Bladder Cancer in the Very Elderly. <i>Anticancer Research</i> , 2017, 37, 3287-3290.	0.5	4
179	Validation of a Score Developed to Estimate the 6-month Survival of Patients Treated with Palliative Local Radiotherapy for Advanced Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 2537-2540.	0.5	0
180	A New Prognostic Tool for Patients Undergoing Radiotherapy plus Upfront Transurethral Resection for Bladder Cancer. <i>In Vivo</i> , 2017, 31, 745-748.	0.6	5

#	ARTICLE	IF	CITATIONS
181	A Survival Score Based on Symptoms and Performance Status for Patients with High-grade Gliomas Receiving Radiochemotherapy. <i>In Vivo</i> , 2017, 31, 689-693.	0.6	3
182	Radiosurgery with a Rotating Gamma System: A Very Effective Treatment for Symptomatic Cerebral Cavernomas. <i>Anticancer Research</i> , 2017, 37, 3729-3733.	0.5	3
183	Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. <i>OMICS Journal of Radiology</i> , 2016, 5, .	0.0	8
184	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 255-264.	2.3	335
185	Excellent outcomes after radiotherapy alone for malignant spinal cord compression from myeloma. <i>Radiology and Oncology</i> , 2016, 50, 337-340.	0.6	21
186	Robustness quantification methods comparison in volumetric modulated arc therapy to treat head and neck cancer. <i>Practical Radiation Oncology</i> , 2016, 6, e269-e275.	1.1	20
187	Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?. <i>Oral Oncology</i> , 2016, 57, 40-45.	0.8	11
188	A New Score for Estimating Survival After Definitive Radiochemotherapy of Limited Disease Small Cell Lung Cancers. <i>Lung</i> , 2016, 194, 625-629.	1.4	7
189	The effect of low hemoglobin levels on outcomes of radiotherapy following microscopically complete resection of locally advanced SCCFN: Implications for the future. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2016, 44, 1441-1444.	0.7	4
190	Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2016, 44, 1436-1440.	0.7	4
191	Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20 mg/m ² cisplatin on five days every four weeks an alternative to 100 mg/m ² cisplatin every three weeks?. <i>Oral Oncology</i> , 2016, 59, 67-72.	0.8	13
192	Results of NCCTG N0275 (Alliance) a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma. <i>Cancer Medicine</i> , 2016, 5, 1890-1896.	1.3	18
193	Best supportive care a reasonable option for patients with brain metastases?. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 722-724.	12.5	0
194	Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m ² for definitive radiochemotherapy of locally advanced head-and-neck cancers. <i>BMC Cancer</i> , 2016, 16, 437.	1.1	22
195	Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy. <i>BJU International</i> , 2016, 118, 236-242.	1.3	3
196	Reply to D.E. Spratt and N. Szerlip. <i>Journal of Clinical Oncology</i> , 2016, 34, 2677-2678.	0.8	0
197	A Survival Score for Patients Receiving Palliative Irradiation for Locally Advanced Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 558-562.	1.1	11
198	Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). <i>Journal of Thoracic Oncology</i> , 2016, 11, 361-369.	0.5	8

#	ARTICLE	IF	CITATIONS
199	A predictive tool particularly designed for elderly myeloma patients presenting with spinal cord compression. <i>BMC Cancer</i> , 2016, 16, 292.	1.1	7
200	Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 505-516.	0.4	125
201	RE: Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv412.	3.0	0
202	A Prognostic Instrument to Estimate the Survival of Elderly Patients Irradiated for Metastatic Epidural Spinal Cord Compression From Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 279-284.	1.1	6
203	Value of Comorbidity Scales for Predicting Survival After Radiochemotherapy of Small Cell Lung Cancer. <i>Lung</i> , 2016, 194, 295-298.	1.4	8
204	Radiotherapy With 4 Gy \times 5 Versus 3 Gy \times 10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01). <i>Journal of Clinical Oncology</i> , 2016, 34, 597-602.	0.8	105
205	Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 523-533.	0.4	103
206	Small Cell Lung Cancer. , 2016, , 798-808.e2.		0
207	An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0151785.	1.1	1
208	A 20-Year Analysis of Clinical Trials Involving Proton Beam Therapy. <i>International Journal of Particle Therapy</i> , 2016, 3, 398-406.	0.9	6
209	Local Therapies Can Improve Intracerebral Control in Patients with Cerebral Metastasis from Gynecological Cancers. <i>Anticancer Research</i> , 2016, 36, 4777-4780.	0.5	3
210	Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer. <i>Anticancer Research</i> , 2016, 36, 4817-4820.	0.5	2
211	A Scoring Instrument to Predict the Survival Prognoses of Patients with Metastatic Epidural Spinal Cord Compression from Gynecological Malignancies. <i>Anticancer Research</i> , 2016, 36, 5469-5472.	0.5	5
212	Comparison of 20 \times 2 Gy and 12 \times 3 Gy for Whole-brain Irradiation of Multiple Brain Metastases from Malignant Melanoma. <i>In Vivo</i> , 2016, 30, 917-920.	0.6	7
213	Radiochemotherapy with Paclitaxel for Recurrent Previously Irradiated Squamous Cell Carcinoma of the Head and Neck. <i>Anticancer Research</i> , 2016, 36, 5463-5468.	0.5	5
214	Prognostic Factors in Patients Irradiated for Recurrent Head-and-Neck Cancer. <i>Anticancer Research</i> , 2016, 36, 6547-6550.	0.5	2
215	Personalized Radiotherapeutic Approaches for Elderly Patients with Epidural Cord Compression from Gastric Cancer. <i>In Vivo</i> , 2016, 30, 69-72.	0.6	2
216	Immunoglobulin G (IgG) Subtype Is Associated with a Favorable Survival Prognosis in Patients Irradiated for Spinal Cord Compression from Myeloma. <i>Anticancer Research</i> , 2016, 36, 375-8.	0.5	0

#	ARTICLE	IF	CITATIONS
217	Estimating the Survival of Elderly Patients with Renal Cell Carcinoma Presenting with Malignant Spinal Cord Compression. <i>Anticancer Research</i> , 2016, 36, 409-13.	0.5	1
218	Karnosky Performance Score and Radiation Dose Predict Survival of Patients Re-irradiated for a Locoregional Recurrence of Small Cell Lung Cancer. <i>Anticancer Research</i> , 2016, 36, 803-5.	0.5	4
219	A Survival Score for Patients Receiving Stereotactic Radiosurgery Alone for Brain Metastases from Breast Cancer. <i>Anticancer Research</i> , 2016, 36, 1073-6.	0.5	5
220	Impact of the Radiation Dose on Survival after Radiochemotherapy for Small-cell Lung Cancer. <i>Anticancer Research</i> , 2016, 36, 1089-91.	0.5	0
221	Impact of the Radiation Dose and Completion of Palliative Radiotherapy on Survival in Patients Treated for Locally Advanced Lung Cancer. <i>Anticancer Research</i> , 2016, 36, 1825-8.	0.5	7
222	Forecasting Survival Probabilities After Radiotherapy of Metastatic Epidural Spinal Cord Compression from Colorectal Cancer in the Elderly. <i>Anticancer Research</i> , 2016, 36, 1829-33.	0.5	2
223	Outcomes After Irradiation of Epidural Spinal Cord Compression Due to Metastatic Thyroid Cancer. <i>Anticancer Research</i> , 2016, 36, 2035-9.	0.5	6
224	Importance of Chemotherapy and Radiation Dose After Microscopically Incomplete Resection of Stage III/IV Head and Neck Cancer. <i>Anticancer Research</i> , 2016, 36, 2487-91.	0.5	1
225	Prognostic Factors After Definitive Radio(Chemo)Therapy of Locally Advanced Head and Neck Cancer. <i>Anticancer Research</i> , 2016, 36, 2523-6.	0.5	2
226	A Total Radiation Dose of 70 Gy Is Required After Macroscopically Incomplete Resection of Squamous Cell Carcinoma of the Head and Neck. <i>Anticancer Research</i> , 2016, 36, 2989-92.	0.5	3
227	Potential Impact of the Overall Treatment Time on Outcomes after Whole-brain Irradiation with 10 \bar{A} –3 Gy for Brain Metastases. <i>Anticancer Research</i> , 2016, 36, 3071-4.	0.5	1
228	Radiation Therapy Alone Provides Excellent Outcomes for Spinal Cord Compression from Vertebral Lymphoma. <i>Anticancer Research</i> , 2016, 36, 3081-3.	0.5	5
229	A new scoring system for predicting survival in patients with non-small cell lung cancer. <i>Cancer Medicine</i> , 2015, 4, 1334-1343.	1.3	26
230	Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1099-1106.	0.5	39
231	Non-small Cell Lung Cancer, Version 6.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 515-524.	2.3	323
232	A new instrument for estimation of survival in elderly patients irradiated for metastatic spinal cord compression from breast cancer. <i>Radiation Oncology</i> , 2015, 10, 173.	1.2	11
233	Number of cerebral lesions predicts freedom from new brain metastases after radiosurgery alone in lung cancer patients. <i>Oncology Letters</i> , 2015, 10, 1109-1112.	0.8	5
234	Single-Fraction Versus 5-Fraction Radiation Therapy for Metastatic Epidural Spinal Cord Compression in Patients With Limited Survival Prognoses: Results of a Matched-Pair Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 368-372.	0.4	17

#	ARTICLE	IF	CITATIONS
235	Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 187-199.	5.1	1,625
236	Predicting the survival probability of gastric cancer patients developing metastatic epidural spinal cord compression (MESCC). <i>Gastric Cancer</i> , 2015, 18, 881-884.	2.7	5
237	A New Tool Predicting Survival After Radiosurgery Alone for One or Two Cerebral Metastases from Lung Cancer. <i>Lung</i> , 2015, 193, 299-302.	1.4	7
238	Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers. <i>Practical Radiation Oncology</i> , 2015, 5, e77-e86.	1.1	75
239	Nuclear expression of p65 (RelA) in patients receiving post-operative radiotherapy for locally advanced squamous cell carcinoma of the head and neck. <i>BMC Cancer</i> , 2015, 15, 102.	1.1	3
240	A matched-pair analysis comparing 5x4 Gy and 10x3 Gy for metastatic spinal cord compression (MSCC) in patients with favorable survival prognoses. <i>Radiation Oncology</i> , 2015, 10, 90.	1.2	2
241	Prophylactic cranial irradiation in elderly patients with small cell lung cancer: Findings from a North Central Cancer Treatment Group pooled analysis. <i>Journal of Geriatric Oncology</i> , 2015, 6, 119-126.	0.5	39
242	Pineal Tumors: Viewpointâ€”Fractionated Radiation Therapy. , 2015, , 469-476.		0
243	International survey of the treatment of metastatic spinal cord compression. <i>Journal of Radiosurgery and SBRT</i> , 2015, 3, 237-245.	0.2	4
244	Radiosurgery with 20 Gy provides better local control of 1-3 brain metastases from breast cancer than with lower doses. <i>Anticancer Research</i> , 2015, 35, 333-6.	0.5	13
245	Predicting survival of patients with metastatic epidural spinal cord compression from cancer of the head-and-neck. <i>Anticancer Research</i> , 2015, 35, 385-8.	0.5	3
246	Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. <i>Anticancer Research</i> , 2015, 35, 3571-4.	0.5	13
247	Predicting Survival After Irradiation of Metastases from Pancreatic Cancer. <i>Anticancer Research</i> , 2015, 35, 4105-8.	0.5	5
248	Defining the Optimal Dose of Stereotactic Radiosurgery for Treating Cerebral Metastases in Elderly Patients. <i>Anticancer Research</i> , 2015, 35, 5701-4.	0.5	0
249	A Tool to Estimate Survival of Elderly Patients Presenting with Metastatic Epidural Spinal Cord Compression (MESCC) from Cancer of Unknown Primary. <i>Anticancer Research</i> , 2015, 35, 6219-22.	0.5	3
250	Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer. <i>Anticancer Research</i> , 2015, 35, 6793-7.	0.5	4
251	Early Outcome of Prostate Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Intra-Prostatic MRI Directed Boost. <i>OMICS Journal of Radiology</i> , 2014, 02, .	0.0	12
252	Do patients with very few brain metastases from breast cancer benefit from whole-brain radiotherapy in addition to radiosurgery?. <i>Radiation Oncology</i> , 2014, 9, 267.	1.2	6

#	ARTICLE	IF	CITATIONS
253	Estimating survival of patients receiving radiosurgery alone for cerebral metastasis from melanoma. <i>Journal of Dermatology</i> , 2014, 41, 918-921.	0.6	2
254	A new prognostic instrument to predict the probability of developing new cerebral metastases after radiosurgery alone. <i>Radiation Oncology</i> , 2014, 9, 215.	1.2	21
255	Prognostic role of the number of involved extraspinal organs in patients with metastatic spinal cord compression. <i>Clinical Neurology and Neurosurgery</i> , 2014, 118, 12-15.	0.6	14
256	Utilization of PSA measurement at three months following salvage radiation therapy to predict future biochemical outcome. <i>Journal of Radiation Oncology</i> , 2014, 3, 81-87.	0.7	0
257	Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2014, 15, 1027-1038.	5.1	200
258	A validated score estimating ambulatory status following radiotherapy of elderly patients for metastatic spinal cord compression. <i>BMC Cancer</i> , 2014, 14, 589.	1.1	7
259	Stereotactic radiosurgery for newly diagnosed brain metastases. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 786-791.	1.0	12
260	Metastatic spinal cord compression. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 919-924.	1.0	9
261	Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 1021-1027.	1.0	5
262	Non-“Small Cell Lung Cancer, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1738-1761.	2.3	156
263	Proton beam therapy for locally advanced lung cancer: A review. <i>World Journal of Clinical Oncology</i> , 2014, 5, 568.	0.9	28
264	Proton beam therapy for localized prostate cancer 101: basics, controversies, and facts. <i>Reviews in Urology</i> , 2014, 16, 67-75.	0.9	13
265	Metastatic spinal cord compression from pancreatic cancer. <i>Anticancer Research</i> , 2014, 34, 3727-30.	0.5	5
266	Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes. <i>Anticancer Research</i> , 2014, 34, 5079-82.	0.5	9
267	Prognostic role of vascular endothelial growth factor and its receptor-1 in patients with esophageal cancer. <i>Anticancer Research</i> , 2014, 34, 5221-6.	0.5	3
268	Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery. <i>Anticancer Research</i> , 2014, 34, 5589-92.	0.5	5
269	Comparison of two dose levels of stereotactic radiosurgery for 1-3 brain metastases from non-small cell lung cancer. <i>Anticancer Research</i> , 2014, 34, 7309-13.	0.5	4
270	Lack of association between COX-2 staining level and biochemical recurrence following salvage radiation therapy for recurrent prostate cancer. <i>Journal of Radiation Oncology</i> , 2013, 2, 309-314.	0.7	0

#	ARTICLE	IF	CITATIONS
271	A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone. <i>Radiotherapy and Oncology</i> , 2013, 108, 123-127.	0.3	36
272	The first survival score for patients with brain metastases from small cell lung cancer (SCLC). <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 2029-2032.	0.6	21
273	The number of involved extracranial organs: A new predictor of survival in breast cancer patients with brain metastasis. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 2108-2110.	0.6	6
274	Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. <i>Lancet Oncology</i> , The, 2013, 14, 619-626.	5.1	203
275	Outcome and Toxicity for Patients Treated with Intensity Modulated Radiation Therapy for Localized Prostate Cancer. <i>Journal of Urology</i> , 2013, 190, 521-526.	0.2	43
276	Charged Particle Radiation Therapy for Uveal Melanoma: A Systematic Review and Meta-Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 18-26.	0.4	86
277	Re: Proton vs Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity. <i>Journal of the National Cancer Institute</i> , 2013, 105, 748-748.	3.0	5
278	A score to identify patients with metastatic spinal cord compression who may be candidates for best supportive care. <i>Cancer</i> , 2013, 119, 897-903.	2.0	54
279	A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528. <i>Journal of Thoracic Oncology</i> , 2013, 8, 79-88.	0.5	44
280	Treatment of Small Cell Lung Cancer. <i>Chest</i> , 2013, 143, e400S-e419S.	0.4	290
281	A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Daily Radiotherapy: CALGB 30904. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1043-1049.	0.5	49
282	Locally Advanced Non-Small Cell Lung Cancer in the Elderly: What Combination of Therapy Is Best?. , 2013, , 173-183.		0
283	Malignant epidural spinal cord compression. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 103-108.	0.5	23
284	Radiation Therapy Modalities for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 450.	3.8	8
285	Brief Report: A Phase II "Window-of-Opportunity" Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study. <i>Journal of Thoracic Oncology</i> , 2012, 7, 919-922.	0.5	46
286	Fibroblast Growth Factor 2 "A Predictor of Outcome for Patients Irradiated for Stage II-III Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 442-447.	0.4	17
287	Risk of Radiation Retinopathy in Patients With Orbital and Ocular Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 1145-1150.	0.4	50
288	Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 2788-2797.	0.8	227

#	ARTICLE	IF	CITATIONS
289	Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancer—A retrospective analysis. <i>Journal of Geriatric Oncology</i> , 2012, 3, 104-110.	0.5	9
290	Single brain metastasis: Resection followed by whole-brain irradiation and a boost to the metastatic site compared to whole-brain irradiation plus radiosurgery. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 326-330.	0.6	20
291	Prognostic factors for different outcomes in patients with metastatic spinal cord compression from cancer of unknown primary. <i>BMC Cancer</i> , 2012, 12, 261.	1.1	22
292	A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. <i>BMC Cancer</i> , 2012, 12, 302.	1.1	41
293	A new score predicting the survival of patients with spinal cord compression from myeloma. <i>BMC Cancer</i> , 2012, 12, 425.	1.1	20
294	Oropharyngeal Cancer Biology and Treatment: Insights From Messenger RNA Sequence Analysis and Transoral Robotic Surgery. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1132.	1.4	1
295	The clinical case for proton beam therapy. <i>Radiation Oncology</i> , 2012, 7, 174.	1.2	48
296	Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer. <i>Prostate</i> , 2012, 72, 1757-1766.	1.2	9
297	Single brain metastasis: Radiosurgery alone compared with radiosurgery plus upfront whole-brain radiotherapy. <i>Cancer</i> , 2012, 118, 2980-2985.	2.0	19
298	Dose escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. <i>Cancer</i> , 2012, 118, 3852-3859.	2.0	38
299	Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. <i>Cancer</i> , 2012, 118, 5358-5365.	2.0	16
300	The prognostic impact of tumor cell expression of estrogen receptor α , progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 157-163.	2.0	46
301	Single brain metastasis: whole-brain irradiation plus either radiosurgery or neurosurgical resection. <i>Cancer</i> , 2012, 118, 1138-1144.	2.0	19
302	Small Cell Lung Cancer. , 2012, , 795-804.		1
303	Radiochemotherapy versus surgery plus radio(chemo)therapy for stage T3/T4 larynx and hypopharynx cancer — Results of a matched-pair analysis. <i>European Journal of Cancer</i> , 2011, 47, 2729-2734.	1.3	32
304	Surgery Followed by Radiotherapy Versus Radiotherapy Alone for Metastatic Spinal Cord Compression From Unfavorable Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e861-e868.	0.4	78
305	Image-Guided Radiotherapy for Prostate Cancer: A Prospective Trial of Concomitant Boost Using Indium-111 α Capromab Pendetide (ProstaScint) Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e423-e429.	0.4	19
306	Shorter-Course Whole-Brain Radiotherapy for Brain Metastases in Elderly Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e469-e473.	0.4	23

#	ARTICLE	IF	CITATIONS
307	Prognostic Impact of Erythropoietin Expression and Erythropoietin Receptor Expression on Locoregional Control and Survival of Patients Irradiated for Stage II/III Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 499-505.	0.4	14
308	Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 626-632.	1.0	36
309	Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 541-547.	1.0	16
310	Dose escalation of radiotherapy for Metastatic Spinal Cord Compression (MSCC) in patients with relatively favorable survival prognosis. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 729-735.	1.0	74
311	Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer. <i>Cancer</i> , 2011, 117, 1262-1271.	2.0	99
312	Final Results of a Prospective Study Comparing the Local Control of Short-Course and Long-Course Radiotherapy for Metastatic Spinal Cord Compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 524-530.	0.4	184
313	Validation of a Score Predicting Post-Treatment Ambulatory Status After Radiotherapy for Metastatic Spinal Cord Compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1503-1506.	0.4	42
314	Evaluation of B7-H3 Expression as a Biomarker of Biochemical Recurrence After Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1343-1349.	0.4	36
315	Scoring Systems to Estimate Intracerebral Control and Survival Rates of Patients Irradiated for Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1122-1127.	0.4	54
316	Comparison of Four Cisplatin-Based Radiochemotherapy Regimens for Nonmetastatic Stage III/IV Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1037-1044.	0.4	35
317	Dose Escalation for Metastatic Spinal Cord Compression in Patients With Relatively Radioresistant Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1492-1497.	0.4	28
318	Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Non-Small-Cell Lung Cancer: Primary Analysis of Radiation Therapy Oncology Group Study RTOG 0214. <i>Journal of Clinical Oncology</i> , 2011, 29, 272-278.	0.8	290
319	Phase III Trial of Prophylactic Cranial Irradiation Compared With Observation in Patients With Locally Advanced Non-Small-Cell Lung Cancer: Neurocognitive and Quality-of-Life Analysis. <i>Journal of Clinical Oncology</i> , 2011, 29, 279-286.	0.8	336
320	Brain Metastases From Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 633-636.	0.6	19
321	Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer: A North Central Cancer Treatment Group-Based Exploratory Study. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1346-1353.	0.5	34
322	Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 3-9.	0.5	37
323	Dose Escalation in Patients Receiving Whole-Brain Radiotherapy for Brain Metastases from Colorectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 70-75.	1.0	21
324	Radiotherapy for Oligometastatic Disease in Patients with Spinal Cord Compression (MSCC) from Relatively Radioresistant Tumors. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 218-223.	1.0	32

#	ARTICLE	IF	CITATIONS
325	Prognostic Impact of VEGF and VEGF Receptor 1 (FLT1) Expression in Patients Irradiated for Stage II/III Non-Small Cell Lung Cancer (NSCLC). <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 307-314.	1.0	14
326	Radiolabeled Cetuximab plus Whole-Brain Irradiation (WBI) for the Treatment of Brain Metastases from Non-Small Cell Lung Cancer (NSCLC). <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 458-462.	1.0	25
327	Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysis. <i>Oral Oncology</i> , 2010, 46, 549-552.	0.8	5
328	Response to the comments on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysis"; <i>Oral Oncology</i> , 2010, 46, 889-890.	0.8	0
329	Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis. <i>BMC Cancer</i> , 2010, 10, 582.	1.1	28
330	The role of postoperative radiotherapy for the treatment of gangliogliomas. <i>Cancer</i> , 2010, 116, 432-442.	2.0	64
331	Validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression. <i>Cancer</i> , 2010, 116, 3670-3673.	2.0	85
332	Reply to the Role of postoperative radiotherapy for the treatment of gangliogliomas. <i>Cancer</i> , 2010, 116, 3071-3072.	2.0	1
333	A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2010, 116, 5686-5693.	2.0	34
334	Salvage Radiotherapy for Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer: Dose-Response Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 735-740.	0.4	104
335	Dose Escalation of Whole-Brain Radiotherapy for Brain Metastases From Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 537-541.	0.4	30
336	Hypofractionated Whole-Brain Radiotherapy for Multiple Brain Metastases From Transitional Cell Carcinoma of the Bladder. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 404-408.	0.4	11
337	Do Patients Receiving Whole-Brain Radiotherapy for Brain Metastases From Renal Cell Carcinoma Benefit From Escalation of the Radiation Dose?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 398-403.	0.4	22
338	Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non-Small-Cell Lung Cancer: NCCTG and SWOG Study N0426. <i>Journal of Clinical Oncology</i> , 2010, 28, 614-619.	0.8	90
339	Matched Pair Analysis Comparing Surgery Followed By Radiotherapy and Radiotherapy Alone for Metastatic Spinal Cord Compression. <i>Journal of Clinical Oncology</i> , 2010, 28, 3597-3604.	0.8	149
340	Treatment of painful bone metastases. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 220-229.	12.5	60
341	Short-course whole-brain radiotherapy (WBRT) for brain metastases due to small-cell lung cancer (SCLC). <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 183-187.	0.6	9
342	Role of radiation therapy in the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 583-586.	1.1	13

#	ARTICLE	IF	CITATIONS
343	Prognostic factors for survival and intracerebral control after irradiation for brain metastases from gynecological cancer. <i>Gynecologic Oncology</i> , 2009, 114, 506-508.	0.6	8
344	Prognostic factors differ by tumor stage for small cell lung cancer. <i>Cancer</i> , 2009, 115, 2721-2731.	2.0	105
345	Radiation dose escalation for localized prostate cancer. <i>Cancer</i> , 2009, 115, 5596-5606.	2.0	49
346	Prostate brachytherapy seed embolization to the right renal artery. <i>Brachytherapy</i> , 2009, 8, 309-312.	0.2	25
347	Radiochemotherapy Including Cisplatin Alone versus Cisplatin + 5-Fluorouracil for Locally Advanced Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 675-681.	1.0	46
348	Preliminary Results of Spinal Cord Compression Recurrence Evaluation (Score-1) Study Comparing Short-Course Versus Long-Course Radiotherapy for Local Control of Malignant Epidural Spinal Cord Compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 228-234.	0.4	93
349	A Matched-Pair Analysis Comparing Whole-Brain Radiotherapy Plus Stereotactic Radiosurgery Versus Surgery Plus Whole-Brain Radiotherapy and a Boost to the Metastatic Site for One or Two Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1077-1081.	0.4	33
350	In Reply to Dr. Stojkovski. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1605.	0.4	0
351	Radioactive EGFR Antibody Cetuximab in Multimodal Cancer Treatment: Stability and Synergistic Effects With Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1226-1231.	0.4	22
352	Evaluation of Ki-67 Staining Levels as an Independent Biomarker of Biochemical Recurrence After Salvage Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1364-1370.	0.4	17
353	In Reply to Belderbos et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 322-323.	0.4	0
354	Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1-3 brain metastases: Results of a matched pair analysis. <i>European Journal of Cancer</i> , 2009, 45, 400-404.	1.3	74
355	Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1075-1082.	0.5	56
356	Comparison of Short-Course versus Long-Course Whole-Brain Radiotherapy in the Treatment of Brain Metastases. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 30-35.	1.0	53
357	Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 198-205.	1.0	30
358	A New Scoring System to Predicting the Survival of Patients Treated with Whole-Brain Radiotherapy for Brain Metastases. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 251-255.	1.0	102
359	Impact of VEGF and VEGF Receptor 1 (FLT1) Expression on the Prognosis of Stage III Esophageal Cancer Patients after Radiochemotherapy*. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 416-420.	1.0	15
360	Vergleich verschiedener Therapieschemata zur Behandlung von 2 Hirnmetastasen bei Älteren Patienten. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 565-571.	1.0	28

#	ARTICLE	IF	CITATIONS
361	Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT + SRS) for one to three brain metastases. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 655-662.	1.0	52
362	Metastatic ependymoma: A multi-institutional retrospective analysis of prognostic factors. <i>Pediatric Blood and Cancer</i> , 2008, 50, 231-235.	0.8	59
363	The first score predicting overall survival in patients with metastatic spinal cord compression. <i>Cancer</i> , 2008, 112, 157-161.	2.0	133
364	Prognostic factors for functional outcome and survival after reirradiation for in-field recurrences of metastatic spinal cord compression. <i>Cancer</i> , 2008, 113, 1090-1096.	2.0	77
365	Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer. <i>Head and Neck</i> , 2008, 30, 235-241.	0.9	37
366	Elective Nodal Irradiation (ENI) Doesn't Appear to Provide a Clear Benefit for Patients With Unresectable Non-Small-Cell Lung Cancer (NSCLC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 311-312.	0.4	20
367	Prognostic Factors Affecting Locally Recurrent Rectal Cancer and Clinical Significance of Hemoglobin. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1087-1093.	0.4	22
368	Locally Advanced Stage IV Squamous Cell Carcinoma of the Head and Neck: Impact of Pre-Radiotherapy Hemoglobin Level and Interruptions During Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1108-1114.	0.4	73
369	Surgical Resection Followed by Whole Brain Radiotherapy Versus Whole Brain Radiotherapy Alone for Single Brain Metastasis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1319-1324.	0.4	46
370	The Impact of Tumor Expression of Erythropoietin Receptors and Erythropoietin on Clinical Outcome of Esophageal Cancer Patients Treated With Chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 152-159.	0.4	22
371	Effect of Smoking During Radiotherapy, Respiratory Insufficiency, and Hemoglobin Levels on Outcome in Patients Irradiated for Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1134-1142.	0.4	38
372	A Score Predicting Posttreatment Ambulatory Status in Patients Irradiated for Metastatic Spinal Cord Compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 905-908.	0.4	80
373	Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. <i>Mayo Clinic Proceedings</i> , 2008, 83, 584-594.	1.4	1,906
374	Defining the Role of Hemithorax Irradiation for Thymomas Is Difficult. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1-2.	0.5	3
375	A comparison of chemotherapy plus surgery with surgery alone for localized esophageal cancer. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 190-191.	4.3	2
376	Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. <i>Mayo Clinic Proceedings</i> , 2008, 83, 584-594.	1.4	2,424
377	Pineal Tumors: Fractionated Radiation Therapy Perspective. , 2008, , 371-376.		0
378	Treatment of Non-small Cell Lung Cancer, Stage IIIB. <i>Chest</i> , 2007, 132, 266S-276S.	0.4	130

#	ARTICLE	IF	CITATIONS
379	Is surgery necessary following chemoradiation for patients with locally advanced cancer of the esophagus?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 506-507.	4.3	8
380	Is stereotactic radiosurgery the best treatment option for patients with spinal metastases?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 400-401.	4.3	6
381	Outcome After Radiotherapy Alone for Metastatic Spinal Cord Compression in Patients With Oligometastases. <i>Journal of Clinical Oncology</i> , 2007, 26, 50-56.	0.8	88
382	Results of a Phase II Study of High-Dose Thoracic Radiation Therapy With Concurrent Cisplatin and Etoposide in Limited-Stage Small-Cell Lung Cancer (NCCTG 95-20-53). <i>Journal of Clinical Oncology</i> , 2007, 25, 3124-3129.	0.8	61
383	Phase I Trial of Sirolimus Combined with Radiation and Cisplatin in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 751-757.	0.5	47
384	D7-07: A phase II NCCTG "Window of Opportunity Front-line" study of the mTOR Inhibitor, CCI-779 (Temsirrolimus) given as a single agent in patients with advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2007, 2, S413.	0.5	20
385	Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis. <i>Mayo Clinic Proceedings</i> , 2007, 82, 364-380.	1.4	291
386	Do Bladder Cancer Patients with Metastatic Spinal Cord Compression Benefit from Radiotherapy Alone?. <i>Urology</i> , 2007, 69, 1081-1085.	0.5	12
387	Spinal cord compression. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 359-370.	2.2	2
388	Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis. <i>Mayo Clinic Proceedings</i> , 2007, 82, 364-380.	1.4	331
389	Lung Cancer in the Elderly. <i>Journal of Clinical Oncology</i> , 2007, 25, 1898-1907.	0.8	133
390	Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment. <i>Mayo Clinic Proceedings</i> , 2007, 82, 490-513.	1.4	119
391	Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. <i>Cancer</i> , 2007, 109, 2515-2521.	2.0	103
392	The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. <i>Cancer</i> , 2007, 110, 363-368.	2.0	54
393	Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients. <i>Cancer</i> , 2007, 110, 1077-1082.	2.0	31
394	Dose escalation beyond 30 grays in 10 fractions for patients with multiple brain metastases. <i>Cancer</i> , 2007, 110, 1345-1350.	2.0	41
395	A boost in addition to whole-brain radiotherapy improves patient outcome after resection of 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. <i>Cancer</i> , 2007, 110, 1551-1559.	2.0	39
396	A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. <i>Cancer</i> , 2007, 110, 1791-1795.	2.0	69

#	ARTICLE	IF	CITATIONS
397	Whole-brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases. <i>Cancer</i> , 2007, 110, 2285-2292.	2.0	88
398	Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients. <i>Cancer</i> , 2007, 110, 2587-2592.	2.0	41
399	Radiotherapy of metastatic spinal cord compression in very elderly patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 256-263.	0.4	35
400	Functional outcome and survival after radiotherapy of metastatic spinal cord compression in patients with cancer of unknown primary. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 532-537.	0.4	39
401	Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 525-531.	0.4	41
402	Central neurocytoma: Management recommendations based on a 35-year experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1145-1154.	0.4	132
403	Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 995-1001.	0.4	11
404	Improved Posttreatment Functional Outcome is Associated with Better Survival in Patients Irradiated for Metastatic Spinal Cord Compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1506-1509.	0.4	13
405	Analysis of Biochemical Control and Prognostic Factors in Patients Treated With Either Low-Dose Three-Dimensional Conformal Radiation Therapy or High-Dose Intensity-Modulated Radiotherapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1053-1058.	0.4	117
406	Reduction of Overall Treatment Time in Patients Irradiated for More Than Three Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1509-1513.	0.4	42
407	Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy. <i>Oral Oncology</i> , 2007, 43, 535-543.	0.8	43
408	Radio(chemo)therapy Plus Resection Versus Radio(chemo)therapy Alone for the Treatment of Stage III Esophageal Cancer*. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 10-16.	1.0	16
409	Experiences with a New High-Dose-Rate Brachytherapy (HDR-BT) Boost Technique for T3b Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 398-402.	1.0	13
410	Whole-Brain Radiotherapy with 20 Gy in 5 Fractions for Brain Metastases in Patients with Cancer of Unknown Primary (CUP). <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 631-636.	1.0	26
411	Salvage Radiotherapy for Isolated Prostate Specific Antigen Increase After Radical Prostatectomy: Evaluation of Prognostic Factors and Creation of a Prognostic Scoring System. <i>Journal of Urology</i> , 2006, 176, 985-990.	0.2	113
412	Combined Prostate Brachytherapy and Short-Term Androgen Deprivation Therapy as Salvage Therapy for Locally Recurrent Prostate Cancer After External Beam Irradiation. <i>Journal of Urology</i> , 2006, 176, 2020-2024.	0.2	73
413	Defining the appropriate radiotherapy regimen for metastatic spinal cord compression in non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 2006, 42, 1052-1056.	1.3	20
414	Innovations in the Radiotherapy of Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 85-92.	0.5	9

#	ARTICLE	IF	CITATIONS
415	Impact of Pretreatment Factors on Adverse Events: A Pooled Analysis of North Central Cancer Treatment Group Advanced Stage Non-small Cell Lung Cancer Trials. <i>Journal of Thoracic Oncology</i> , 2006, 1, 556-563.	0.5	7
416	Innovations in the Radiotherapy of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 85-92.	0.5	11
417	Prognostic factors predicting functional outcomes, recurrence-free survival, and overall survival after radiotherapy for metastatic spinal cord compression in breast cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 182-188.	0.4	57
418	Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1452-1457.	0.4	66
419	Epoetin alfa improves survival after chemoradiation for Stage III esophageal cancer: Final results of a prospective observational study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 459-465.	0.4	25
420	Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1106-1111.	0.4	119
421	Treatment recommendations for the various subgroups of neurocytomas. <i>Journal of Neuro-Oncology</i> , 2006, 77, 305-309.	1.4	81
422	Dose-response relationship for fractionated irradiation in the treatment of spinal meningeal melanocytomas: a review of the literature. <i>Journal of Neuro-Oncology</i> , 2006, 77, 311-314.	1.4	41
423	Is 50 Gy Sufficient to Achieve Long-Term Local Control after Incomplete Resection of Typical Neurocytomas?. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 415-418.	1.0	15
424	Short-Course Radiotherapy (RT) for Metastatic Spinal Cord Compression (MSCC) Due to Renal Cell Carcinoma: Results of a Retrospective Multi-Center Study. <i>European Urology</i> , 2006, 49, 846-852.	0.9	22
425	Value of postoperative stereotactic radiosurgery and conventional radiotherapy for incompletely resected typical neurocytomas. <i>Cancer</i> , 2006, 106, 1140-1143.	2.0	52
426	A prognostic model for advanced stage nonsmall cell lung cancer. <i>Cancer</i> , 2006, 107, 781-792.	2.0	99
427	Prognostic Factors for Local Control and Survival After Radiotherapy of Metastatic Spinal Cord Compression. <i>Journal of Clinical Oncology</i> , 2006, 24, 3388-3393.	0.8	292
428	Impact of Pretreatment Factors on Adverse Events: A Pooled Analysis of North Central Cancer Treatment Group Advanced Stage Non-small Cell Lung Cancer Trials. <i>Journal of Thoracic Oncology</i> , 2006, 1, 556-563.	0.5	14
429	Innovations in the radiotherapy of non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 85-92.	0.5	5
430	Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 60-63.	0.4	16
431	The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 1432-1437.	0.4	14
432	Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy. <i>Cancer</i> , 2005, 103, 1740-1746.	2.0	22

#	ARTICLE	IF	CITATIONS
433	Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. <i>Cancer</i> , 2005, 103, 2349-2354.	2.0	76
434	Epoetin- α during radiotherapy for stage III esophageal carcinoma. <i>Cancer</i> , 2005, 103, 2274-2279.	2.0	12
435	Well-differentiated neurocytoma: What is the best available treatment?. <i>Neuro-Oncology</i> , 2005, 7, 77-83.	0.6	74
436	Should Elderly Non-Small-Cell Lung Cancer Patients Be Offered Elderly-Specific Trials? Results of a Pooled Analysis From the North Central Cancer Treatment Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 9113-9119.	0.8	116
437	Evaluation of Five Radiation Schedules and Prognostic Factors for Metastatic Spinal Cord Compression. <i>Journal of Clinical Oncology</i> , 2005, 23, 3366-3375.	0.8	323
438	Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5929-5937.	0.8	66
439	Dose-effect relationship for radiotherapy after incomplete resection of atypical neurocytomas. <i>Radiotherapy and Oncology</i> , 2005, 74, 67-69.	0.3	10
440	Prognostic value of the MIB-1 labeling index for central neurocytomas. <i>Neurology</i> , 2004, 62, 987-989.	1.5	87
441	Treatment of atypical neurocytomas. <i>Cancer</i> , 2004, 100, 814-817.	2.0	86
442	Therapy of meningeal melanocytomas. <i>Cancer</i> , 2004, 100, 2442-2447.	2.0	76
443	A prospective evaluation of two radiotherapy schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression. <i>Cancer</i> , 2004, 101, 2687-2692.	2.0	93
444	Defining the best available treatment for neurocytomas in children. <i>Cancer</i> , 2004, 101, 2629-2632.	2.0	30
445	Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1530-1535.	0.4	29
446	Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 943-951.	0.4	172
447	Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 24-29.	0.4	28
448	Treatment planning for dose escalation in non-small cell lung cancer (NSCLC). <i>Medical Dosimetry</i> , 2004, 29, 196-203.	0.4	5
449	Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: Do outcomes differ?. <i>Urology</i> , 2004, 64, 760-764.	0.5	43
450	Radiotherapy for a rising PSA following radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 57-61.	0.8	5

#	ARTICLE	IF	CITATIONS
451	Breast-conserving therapy and sentinel lymph node biopsy are feasible in cancer patients with previous implant breast augmentation. American Journal of Surgery, 2004, 188, 122-125.	0.9	56
452	Acute and Chronic Results of Adjuvant Radiotherapy After Mastectomy and Transverse Rectus Abdominis Myocutaneous (TRAM) Flap Reconstruction for Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 389-394.	0.6	33
453	Rectal cancer: preoperative versus postoperative irradiation as a component of adjuvant treatment. Seminars in Radiation Oncology, 2003, 13, 419-432.	1.0	17
454	In response to Drs. Kopelson et al. International Journal of Radiation Oncology Biology Physics, 2003, 55, 282.	0.4	0
455	Defining the optimal dose of radiation after incomplete resection of central neurocytomas. International Journal of Radiation Oncology Biology Physics, 2003, 55, 373-377.	0.4	37
456	In response to Dr. Beitler. International Journal of Radiation Oncology Biology Physics, 2003, 55, 1460-1461.	0.4	0
457	Radiotherapy for Men With Isolated Increase in Serum Prostate Specific Antigen After Radical Prostatectomy. Journal of Urology, 2003, 170, 1833-1837.	0.2	60
458	O-238 The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years. Lung Cancer, 2003, 41, S70.	0.9	9
459	The Outcome of Combined-Modality Therapy for Stage III Non-Small-Cell Lung Cancer in the Elderly. Journal of Clinical Oncology, 2003, 21, 3201-3206.	0.8	223
460	Endocavitary Radiation Therapy for Rectal Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 508-512.	0.6	20
461	Salvage Radiotherapy for Elevated PSA Levels Following Prostatectomy. Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBT /Overlock 1.0	1.0	14
462	Malignant Pineal Parenchymal Tumors in Adult Patients: Patterns of Care and Prognostic Factors. Neurosurgery, 2002, 51, 44-56.	0.6	133
463	Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic experience. Journal of Surgical Oncology, 2002, 80, 19-25.	0.8	126
464	Benign central neurocytoma a double misnomer?. Cancer, 2002, 94, 284-284.	2.0	4
465	In regard to the radiotherapy of myxopapillary ependymomas. International Journal of Radiation Oncology Biology Physics, 2002, 53, 787.	0.4	24
466	Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer 1 This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Additional participating institutions included Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Meritcare Hospital CCOP, Fargo, ND; Sioux Community Cancer Consortium, Sioux Falls, SD; Geisinger Clinical Oncology Program, Danville, PA (Suresh Nair.) Tj ETQq0.0.0 rgBT /Overlock 10 Tf 5	0.4	95
467	Phase I study of hyperfractionated accelerated radiotherapy and escalating doses of daily cisplatin for patients with locally advanced non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2002, 54, 729-734.	0.4	5
468	Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. International Journal of Radiation Oncology Biology Physics, 2002, 52, 167-175.	0.4	150

#	ARTICLE	IF	CITATIONS
469	THE ROLE OF RADIOTHERAPY AFTER RADICAL PROSTATECTOMY. Urologic Clinics of North America, 2001, 28, 629-637.	0.8	8
470	Radiation therapy (RT) after prostatectomy: The case for salvage therapy as opposed to adjuvant therapy. International Journal of Cancer, 2001, 96, 94-98.	2.3	29
471	Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2000, 46, 109-118.	0.4	35
472	Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2000, 46, 589-598.	0.4	42
473	RADIOTHERAPY FOR ISOLATED SERUM PROSTATE SPECIFIC ANTIGEN ELEVATION AFTER PROSTATECTOMY FOR PROSTATE CANCER. Journal of Urology, 2000, 163, 845-850.	0.2	197
474	RADIOTHERAPY FOR ISOLATED SERUM PROSTATE SPECIFIC ANTIGEN ELEVATION AFTER PROSTATECTOMY FOR PROSTATE CANCER. Journal of Urology, 2000, , 845.	0.2	3
475	Laparoscopic Radical Parametrectomy and Pelvic and Aortic Lymphadenectomy for Vaginal Carcinoma: A Case Report. Gynecologic Oncology, 1999, 75, 514-516.	0.6	31
476	Metastatic spinal cord compression in patients with colorectal cancer. Journal of Neuro-Oncology, 1999, 44, 175-180.	1.4	49
477	The results of radiotherapy for brainstem tumors. Journal of Neuro-Oncology, 1998, 40, 171-177.	1.4	25
478	Radiation therapy after prostatectomy: Now or later?. Seminars in Radiation Oncology, 1998, 8, 132-139.	1.0	29
479	Malignant peripheral nerve sheath tumor: analysis of treatment outcome. International Journal of Radiation Oncology Biology Physics, 1998, 42, 351-360.	0.4	370
480	The results of radiotherapy for ependymomas: the mayo clinic experience. International Journal of Radiation Oncology Biology Physics, 1998, 42, 953-958.	0.4	172
481	Radiation therapy for histologically confirmed primary central nervous system germinoma. International Journal of Radiation Oncology Biology Physics, 1997, 38, 915-923.	0.4	117
482	Stereotactic radiosurgery for glomus jugulare tumors: A preliminary report. International Journal of Radiation Oncology Biology Physics, 1997, 38, 491-495.	0.4	81
483	The role of retrograde urethrography in the planning of prostate cancer radiotherapy. Medical Dosimetry, 1997, 22, 83-86.	0.4	5
484	The treatment of locally advanced colon cancer. International Journal of Radiation Oncology Biology Physics, 1997, 37, 51-58.	0.4	47
485	Central neurocytomas. , 1997, 79, 790-795.		162
486	The Use of Radiotherapy for Patients with Isolated Elevation of Serum Prostate Specific Antigen Following Radical Prostatectomy. Journal of Urology, 1996, 156, 1725-1729.	0.2	124

#	ARTICLE	IF	CITATIONS
487	Evaluation of Serum Prostate-Specific Antigen Levels After Postoperative Radiation Therapy for Pathologic Stage T3, NO Prostate Cancer. Mayo Clinic Proceedings, 1996, 71, 242-248.	1.4	15
488	Analysis of outcome in patients reirradiated for brain metastases. International Journal of Radiation Oncology Biology Physics, 1996, 34, 585-590.	0.4	143
489	Histologically confirmed pineal tumors and other germ cell tumors of the brain. , 1996, 78, 2564-2571.		151
490	Endocavitary radiotherapy of rectal cancer. International Journal of Radiation Oncology Biology Physics, 1996, 34, 677-682.	0.4	32
491	The results of radical retropubic prostatectomy and adjuvant therapy for pathologic Stage C prostate cancer. International Journal of Radiation Oncology Biology Physics, 1996, 34, 535-541.	0.4	82
492	Nongerminomatous germ cell tumors of the brain. International Journal of Radiation Oncology Biology Physics, 1996, 36, 557-563.	0.4	60
493	Regarding postoperative radiotherapy for pathologic stage C prostate cancer: In response to Dr. Lawrence and Mr. Collins. International Journal of Radiation Oncology Biology Physics, 1996, 36, 757-758.	0.4	0
494	Tonsil cancer. Patterns of failure after surgery alone and surgery combined with postoperative radiation therapy. Cancer, 1994, 73, 2638-2647.	2.0	44
495	Radiotherapy for Isolated Increases in Serum Prostate-Specific Antigen Levels After Radical Prostatectomy. Mayo Clinic Proceedings, 1994, 69, 613-619.	1.4	70
496	Pineal parenchymal tumors: Clinical, pathologic, and therapeutic aspects. Cancer, 1993, 72, 870-880.	2.0	234
497	Movements of the Prostate Due to Rectal and Bladder Distension: Implications for Radiotherapy. Medical Dosimetry, 1993, 18, 13-15.	0.4	92
498	Radiotherapy Treatment Planning for Prostate Cancer in Patients with Prosthetic Hips. Medical Dosimetry, 1992, 17, 83-86.	0.4	19
499	Results of Radiotherapy for Chemodectomas. Mayo Clinic Proceedings, 1992, 67, 537-540.	1.4	68
500	The results of radiotherapy for isolated elevation of serum PSA levels following radical prostatectomy. International Journal of Radiation Oncology Biology Physics, 1992, 23, 141-145.	0.4	31
501	Long-term survival and patterns of failure after postoperative radiation therapy for subtotally resected rectal adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 1989, 16, 459-463.	0.4	56
502	Postoperative adjuvant therapy of rectal cancer: An analysis of disease control, survival, and prognostic factors. International Journal of Radiation Oncology Biology Physics, 1989, 17, 55-62.	0.4	64
503	Pediatric Pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. Neuro-Oncology Advances, 0, , .	0.4	6
504	Toxicity and outcomes after external beam irradiation for prostate cancer in patients with prior holmium laser enucleation of the prostate: Early experience. Cancer Reports, 0, , .	0.6	2